Using Gold Nanoparticles to Treat B-Chronic Lymphocytic Leukemia
Author Information
Author(s): Priyabrata Mukherjee, Resham Bhattacharya, Nancy Bone, Yean K Lee, Chitta Ranjan Patra, Shanfeng Wang, Lichun Lu, Charla Secreto, Pataki C Banerjee, Michael J Yaszemski, Neil E Kay, Debabrata Mukhopadhyay
Primary Institution: Mayo Clinic
Hypothesis
Can gold nanoparticles enhance the effectiveness of anti-VEGF antibodies in inducing apoptosis in CLL B cells?
Conclusion
Gold nanoparticles conjugated with anti-VEGF antibodies significantly increase apoptosis in CLL B cells compared to controls.
Supporting Evidence
- All patient samples studied responded to the gold-AbVF treatment with dose-dependent apoptosis of CLL B cells.
- Gold-AbVF treated cells showed significant downregulation of anti-apoptotic proteins.
- Significant increases in apoptosis (~80%) were observed in 4 out of the 7 CLL samples treated with gold-AbVF.
Takeaway
Scientists are using tiny gold particles to help a medicine kill cancer cells better. This could make treatments for leukemia more effective.
Methodology
The study involved synthesizing gold nanoparticles, conjugating them with anti-VEGF antibodies, and testing their effects on CLL B cells from patients.
Potential Biases
Potential bias due to the small number of patient samples and lack of control groups for all variables.
Limitations
The study was conducted on a small sample size and lacked a preclinical model for CLL-B.
Participant Demographics
Patients with B-chronic lymphocytic leukemia, not treated for at least 6 weeks prior to the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website